Ultragenyx Pharma (RARE) Tops Q1 EPS by 8c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.63), $0.08 better than the analyst estimate of ($1.71).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c